AR and pachyonychia congenita: Since 2018, the U.S. Food and Drug Administration (FDA) approved three androgen receptor (AR) inhibitors—apalutamide, enzalutamide, and darolutamide—for the treatment of non-metastatic castration-resistant PC (nmCRPC, also known as M0 CRPC).